Esmya / Ulipristal Acetate Gedeon Richter - direct healthcare professional communication (DHPC)

ulipristal acetate

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Ulipristal acetate 5 mg for uterine fibroids not to be used during ongoing review of liver injury risk

Key facts

• Medicine name:
  • Esmya
  • Ulipristal Acetate Gedeon Richter
• Active substance:
  ulipristal acetate
• Therapeutic area (MeSH):
  Leiomyoma
• Procedure number:
  EMEA/H/A-31/1496
• Regulatory outcome:
  Suspension
• DHPC type:
  Interim measures
• Dissemination date:
  23/03/2020